ALIA-1758 vs Trontinemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALIA-1758
Developed by AbbVie
NCT06406348 · Phase 1 · completed
The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.
No aligned efficacy figure on record for this race.
Trontinemab
Developed by Roche
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2027 · NCT04639050 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALIA-1758 | Trontinemab |
|---|---|---|
| CDR-SB, change | —Not reported | —Trial running · NCT07170150 |
| ADAS-Cog11, change | —Not reported | —Trial running · NCT07170150 |
| ADCS-ADL, change | —Not reported | —Trial running · NCT07170150 |
| MMSE, change | —Not reported | —Trial running · NCT07170150 |
| Amyloid PET, change (centiloids) | —Not reported | —Trial running · NCT07170150 |
CDR-SB, change
- ALIA-1758
- —Not reported
- Trontinemab
- —Trial running · NCT07170150
ADAS-Cog11, change
- ALIA-1758
- —Not reported
- Trontinemab
- —Trial running · NCT07170150
ADCS-ADL, change
- ALIA-1758
- —Not reported
- Trontinemab
- —Trial running · NCT07170150
MMSE, change
- ALIA-1758
- —Not reported
- Trontinemab
- —Trial running · NCT07170150
Amyloid PET, change (centiloids)
- ALIA-1758
- —Not reported
- Trontinemab
- —Trial running · NCT07170150
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALIA-1758: no structured comparison results are available for Alzheimer's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALIA-1758: 0 of 4 rows · Trontinemab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Trontinemab |
|---|---|
| Dropout rate | 0%7.2 mg/kga NCT04023994 · Phase 1 · registry result, not featured evidence show 4 more results0%3.6 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence 16.7%1.2 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence 50%0.4 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence 25%0.1 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —7.2 mg/kga NCT04023994 · Phase 1 · registry result, not featured evidence show 4 more results—3.6 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence —1.2 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence —0.4 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence —0.1 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%7.2 mg/kga NCT04023994 · Phase 1 · registry result, not featured evidence show 4 more results0%3.6 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence 0%1.2 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence 0%0.4 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence 0%0.1 mg/kg NCT04023994 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 7.2 mg/kga infusion related reaction 100% (placebo 10%) headache 50% (placebo 50%) injection site extravasation 16.7% (placebo 0%) NCT04023994 · Phase 1 · registry result, not featured evidence show 4 more results3.6 mg/kg infusion related reaction 83.3% (placebo 10%) nausea 33.3% (placebo 30%) back pain 16.7% (placebo 0%) NCT04023994 · Phase 1 · registry result, not featured evidence 1.2 mg/kg headache 83.3% (placebo 50%) back pain 50% (placebo 0%) nausea 50% (placebo 30%) NCT04023994 · Phase 1 · registry result, not featured evidence 0.4 mg/kg back pain 25% (placebo 0%) headache 25% (placebo 50%) arthralgia 0% (placebo 10%) NCT04023994 · Phase 1 · registry result, not featured evidence 0.1 mg/kg back pain 75% (placebo 0%) arthralgia 0% (placebo 10%) chills 0% (placebo 0%) NCT04023994 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · Trontinemab's landscape